Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.77% | 3.47% | -7.13% | -10.73% | 9.30% |
| Total Depreciation and Amortization | -3.14% | -1.37% | 20.67% | 67.97% | 218.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.77% | 6.41% | 50.38% | 19.19% | -9.99% |
| Change in Net Operating Assets | 11.96% | -19.73% | 145.53% | 125.38% | -165.20% |
| Cash from Operations | 4.88% | 2.48% | 6.03% | -0.89% | -11.32% |
| Capital Expenditure | -- | 100.00% | 100.00% | 92.58% | 83.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 100.00% | 92.58% | 83.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.73% | -93.90% | -96.25% | -98.75% | 178.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.10% | 96.79% | 98.02% | 97.51% | -103.21% |
| Cash from Financing | -68.69% | -93.65% | -96.09% | -98.86% | 188.36% |
| Foreign Exchange rate Adjustments | 166.20% | -218.44% | 140.20% | 94.40% | 14.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -763.94% | -1,496.81% | -1,303.43% | -1,025.23% | 117.40% |